Tag: pharmaceuticals
Lantheus Stock Analysis: Buy or Sell? Valuation, Margins & Growth
Lantheus (LNTH) is rated Hold because strong cash generation and a low-debt balance sheet are offset by uneven quarterly revenue growth. Its 24.1x trailing P/E and 16.9x EV/EBITDA leave less room for disappointment.
Teva Pharmaceutical Stock Analysis: Buy or Sell? Valuation, Growth & Margins
Teva Pharmaceutical Industries Ltd. (TEVA) is rated Hold as the stock has already rerated on an earnings recovery, while revenue still faces generic pricing pressure. The business generates solid cash flow and strong EBITDA margins, but execution on branded growth and the AUSTEDO pricing reset remain key risks.
Incyte Stock Analysis: Valuation, Patent Cliff, Cash Flow & Growth
Incyte (INCY) is rated Hold as strong cash generation and reasonable valuation are offset by the looming 2028 JAKAFI patent cliff. The company is profitable, but investors need OPZELURA, ZYNYZ and NIKTIMVO to scale fast enough to replace legacy franchise erosion.